Lescol Related Published Studies
Well-designed clinical trials related to Lescol (Fluvastatin)
Fluvastatin and perioperative events in patients undergoing vascular surgery. [2009.09.03]
Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. [2009.07]
Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). [2009.06]
Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. [2009.04]
Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. [2009.03]
Fluvastatin treatment and withdrawal: effects on endothelial function. [2008.10]
Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. [2008.09]
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. [2008.09]
Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. [2008.07.15]
Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. [2008.05.06]
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. [2007.09]
Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. [2007.09]
Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. [2007.06]
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. [2007.06]
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. [2006.11]
Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. [2006.10]
The cost-effectiveness of fluvastatin in hungary following successful percutaneous coronary intervention. [2006.08]
The Cost-Effectiveness of Fluvastatin in Hungary Following Successful Percutaneous Coronary Intervention. [2006.06.21]
Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. [2006.06]
The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. [2006.06]
Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. [2006.05]
The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. [2006.03]
Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. [2005.11]
Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes. [2005.11]
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. [2005.09]
Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. [2005.09]
Efficacy and safety of slow-release fluvastatin 80 mg daily in Chinese patients with hypercholesterolemia. [2005.08]
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. [2005.08]
Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. [2005.03.24]
[The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome] [2005.03]
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). [2005.02.15]
Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. [2005.02]
No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. [2005.02]
Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. [2005.02]
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. [2005.01.27]
A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia. [2005]
Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. [2004.12]
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. [2004.10]
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. [2004.10]
Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). [2004.10]
Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. [2004.07]
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. [2004.06]
Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. [2004.04]
Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. [2004.03]
Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. [2004.03]
Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. [2004.02]
Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. [2004.01.01]
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. [2004.01.01]
An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. [2004]
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. [2003.11]
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. [2003.08]
Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. [2003.08]
Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. [2003.07]
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. [2003.06.14]
The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI. [2003.06]
Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. [2003.05]
[Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia] [2003.04]
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. [2003.04]
[Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia] [2003.04]
Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. [2003.03]
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. [2002.12]
Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. [2002.12]
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. [2002.11]
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. [2002.06.26]
Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. [2002.02]
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. [2002.01]
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. [2001.12]
Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. [2001.11]
The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. [2001.10]
Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. [2001.05]
Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. [2001.04.17]
Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). [2001.04.03]
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. [2001.04]
Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. [2001.04]
Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. [2001.04]
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. [2001.03]
Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. [2001.03]
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. [2001.02.15]
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. [2001.02]
Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. [2001.01]
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. [2001]
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. [2000.10.01]
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. [2000.06]
Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). [2000.06]
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. [2000.05]
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. [2000.04]
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. [2000.04]
Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects. [2000.03]
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. [2000.03]
Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. [2000.01.01]
Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. [2000.01]
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. [2000.01]
Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. [1999.10.15]
Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. [1999.06]
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. [1999.05]
A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. [1999.05]
[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate] [1999.04]
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. [1999.02.16]
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. [1999.01]
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. [1998.09]
A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. [1998.07]
|
